ARGENX SE - ADR (ARGX) Stock News
NASDAQ:ARGX - Nasdaq - US04016X1019 - ADR - Currency: USD
ARGX Latest News, Press Relases and Analysis
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Mentions: JAZZ
Is Ascendis Pharma A/S (ASND) the Best Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Ascendis Pharma A/S (NASDAQ:ASND) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been […]
Is Argenx SE (ARGX) the Best Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been on […]
Is Datadog, Inc. (DDOG) the Best Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Datadog, Inc. (NASDAQ:DDOG) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been on […]
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
April 11, 2025, 10:01 PM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving...
argenx Announces Annual General Meeting of Shareholders on May 27, 2025
Argenx Bounds Off 200-Day Line On 'Best-Case Scenario' For Blockbuster Drug
The prefilled syringe will cost 4% more than the under-the-skin shot.
JAZZ or ARGX: Which Is the Better Value Stock Right Now?
JAZZ vs. ARGX: Which Stock Is the Better Value Option?
Mentions: JAZZ
argenx Announces FDA Approval of VYVGART Hytrulo Prefilled Syringe for Self-Injection in Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringeSelf-injection...
argenx SE (ARGX): Among the Aggressive Stocks Picked by Hedge Funds
We recently published a list of Aggressive Stock Portfolio: 12 Stocks Picked by Hedge Funds. In this article, we are going to take a look at where argenx SE (NASDAQ:ARGX) stands against other aggressive stocks picked by hedge funds. The broader market has dropped into correction territory, declining by over 10% from its peak in […]
Is Insmed Incorporated (INSM) the Best Long Term Growth Stock to Buy According to Billionaires?
We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Insmed Incorporated (NASDAQ:INSM) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive orders with […]
argenx Highlights VYVGART Data at AAN 2025 Setting New Standard in Sustained Efficacy and Improved Quality of Life Measures for Patients Living with gMG and CIDP
ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG...
Is Argenx SE (ARGX) The Most Profitable Biotech Stock To Buy Right Now?
We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a look at where Argenx SE (NASDAQ:ARGX) stands against other most profitable biotech stocks to buy right now. With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is […]
Mentions: TSLA
argenx Highlights FcRn Leadership with Long-term Data and Transformational Patient Outcomes at the American Academy of Neurology 2025 Annual Meeting
Largest safety data set on FcRn blocking demonstrates consistent, favorable safety profile of VYVGART and VYVGART HytrulogMG patients on VYVGART achieve...
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Analysts remains bullish on the company's chances in depression and epilepsy. But investors aren't convinced.
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
$737 million in fourth quarter and $2.2 billion in full year global product net sales Received positive CHMP recommendation for VYVGART pre-filled syringe...
argenx Reports Full Year 2024 Financial Results and Provides Fourth Quarter Business Update
argenx to Present at TD Cowen 45th Annual Healthcare Conference
February 25, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx to Present at TD Cowen 45th Annual Healthcare Conference
argenx to Report Full Year 2024 Financial Results and Fourth Quarter Business Update on February 27, 2025
February 20, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...